schliessen

Filtern

 

Bibliotheken

Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.

BACKGROUNDThe analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each other in terms of cost per life year saved. In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide... Full description

Journal Title: European journal of clinical pharmacology 1996, Vol.51(2), pp.111-116
Main Author: Messori, A
Other Authors: Becagli, P , Trippoli, S , Tendi, E
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0031-6970
Link: http://search.proquest.com/docview/78520084/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest78520084
title: Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
format: Article
creator:
  • Messori, A
  • Becagli, P
  • Trippoli, S
  • Tendi, E
subjects:
  • Antineoplastic Combined Chemotherapy Protocols–Economics
  • Breast Neoplasms–Therapeutic Use
  • Chemotherapy, Adjuvant–Drug Therapy
  • Cost-Benefit Analysis–Economics
  • Cyclophosphamide–Mortality
  • Drug Administration Schedule–Pathology
  • Female–Economics
  • Fluorouracil–Administration & Dosage
  • Humans–Administration & Dosage
  • Lymph Nodes–Pathology
  • Lymphatic Metastasis–Administration & Dosage
  • Methotrexate–Administration & Dosage
  • Sensitivity and Specificity–Administration & Dosage
  • Survival Rate–Administration & Dosage
ispartof: European journal of clinical pharmacology, 1996, Vol.51(2), pp.111-116
description: BACKGROUNDThe analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each other in terms of cost per life year saved. In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+...
language: eng
source:
identifier: ISSN: 0031-6970
fulltext: fulltext
issn:
  • 00316970
  • 0031-6970
url: Link


@attributes
ID282877927
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid78520084
sourceidproquest
recordidTN_proquest78520084
sourcesystemPC
pqid78520084
display
typearticle
titleCost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
creatorMessori, A ; Becagli, P ; Trippoli, S ; Tendi, E
contributorMessori, A (correspondence author) ; Messori, A (record owner)
ispartofEuropean journal of clinical pharmacology, 1996, Vol.51(2), pp.111-116
identifierISSN: 0031-6970
subject
descriptionBACKGROUNDThe analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each other in terms of cost per life year saved. In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+...
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/78520084/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Messori, A
1Becagli, P
2Trippoli, S
3Tendi, E
titleCost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
descriptionBACKGROUNDThe analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each other in terms of cost per life year saved. In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+...
subject
0Antineoplastic Combined Chemotherapy Protocols–Economics
1Breast Neoplasms–Therapeutic Use
2Chemotherapy, Adjuvant–Drug Therapy
3Cost-Benefit Analysis–Economics
4Cyclophosphamide–Mortality
5Drug Administration Schedule–Pathology
6Female–Economics
7Fluorouracil–Administration & Dosage
8Humans–Administration...
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
12Environmental Science Index (ProQuest)
13Biological Science Index (ProQuest)
14Environmental Science Collection (ProQuest)
sourceidproquest
recordidproquest78520084
issn
000316970
10031-6970
rsrctypearticle
creationdate1996
addtitleEuropean journal of clinical pharmacology
searchscope
01007489
11007527
21007944
31009130
410000004
510000006
610000038
710000043
810000050
910000120
1010000159
1110000198
1210000200
1310000209
1410000217
1510000234
1610000238
1710000253
1810000260
1910000270
2010000271
2110000302
2210000349
2310000350
2410000354
25proquest
scope
01007489
11007527
21007944
31009130
410000004
510000006
610000038
710000043
810000050
910000120
1010000159
1110000198
1210000200
1310000209
1410000217
1510000234
1610000238
1710000253
1810000260
1910000270
2010000271
2110000302
2210000349
2310000350
2410000354
25proquest
lsr43
01007489false
11007527false
21007944false
31009130false
410000004false
510000006false
610000038false
710000043false
810000050false
910000120false
1010000159false
1110000198false
1210000200false
1310000209false
1410000217false
1510000234false
1610000238false
1710000253false
1810000260false
1910000270false
2010000271false
2110000302false
2210000349false
2310000350false
2410000354false
contributorMessori, A
startdate19960101
enddate19960101
citationpf 111 pt 116 vol 51 issue 2
lsr30VSR-Enriched:[doi, eissn, pqid]
sort
titleCost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
authorMessori, A ; Becagli, P ; Trippoli, S ; Tendi, E
creationdate19960101
lso0119960101
facets
frbrgroupid4445857929373183300
frbrtype5
newrecords20181218
languageeng
creationdate1996
topic
0Antineoplastic Combined Chemotherapy Protocols–Economics
1Breast Neoplasms–Therapeutic Use
2Chemotherapy, Adjuvant–Drug Therapy
3Cost-Benefit Analysis–Economics
4Cyclophosphamide–Mortality
5Drug Administration Schedule–Pathology
6Female–Economics
7Fluorouracil–Administration & Dosage
8Humans–Administration...
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Environmental Science Index (ProQuest)
12Biological Science Index (ProQuest)
13Environmental Science Collection (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Messori, A
1Becagli, P
2Trippoli, S
3Tendi, E
jtitleEuropean journal of clinical pharmacology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Messori
1Becagli
2Trippoli
3Tendi
aufirst
0A
1P
2S
3E
au
0Messori, A
1Becagli, P
2Trippoli, S
3Tendi, E
addauMessori, A
atitleCost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
jtitleEuropean journal of clinical pharmacology
risdate19960101
volume51
issue2
spage111
epage116
pages111-116
issn0031-6970
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDThe analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each other in terms of cost per life year saved. In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+...
urlhttp://search.proquest.com/docview/78520084/
doi10.1007/s002280050169
eissn14321041
date1996-01-01